Industry Newsbase editinggene therapybeam therapeuticsstrategic financing
Beam Therapeutics Raises Financing, Targets BLA Submission
5.1
Relevance Score
Beam Therapeutics Inc. reported fiscal Q4 and full-year 2025 results on Feb. 24, announced a new BEAM-304 program for phenylketonuria, and said it targets a BLA submission this year for a sickle cell therapy. On Feb. 25, RBC raised the price target to $26, and the company secured long-term non-dilutive financing from Sixth Street with $1.25 billion cash on hand.
